CRISPR Therapeutics AG (CRSP)

55.89 +0.82 (+1.49%) 收市：04:00PM EDT

CRISPR Therapeutics AG

Baarerstrasse 14
Zug 6300
Switzerland
41 41 561 32 77
https://www.crisprtx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 407

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Samarth Kulkarni Ph.D.	CEO & Chairman	1.35M	4.06M	1978
Dr. Raju Yashaswi Prasad Ph.D.	Chief Financial Officer	880.1k	無	1984
Mr. James R. Kasinger	General Counsel & Secretary	734.72k	無	1972
Mr. Shaun Foy	Founder	無	無	無
Dr. Emmanuelle Marie Charpentier	Co-Founder & Scientific Advisory Board Member	無	無	無
Dr. Craig C. Mello Ph.D.	Scientific Founder & Advisory Board Member	無	無	無
Dr. Chad A. Cowan Ph.D.	Scientific Founder	無	無	無
Dr. Matthew Porteus M.D., Ph.D.	Scientific Founder & Advisory Board Member	無	無	1966
Dr. Daniel G. Anderson Ph.D.	Scientific Founder & Advisory Board Member	無	無	無
Mr. Stephen Kennedy	Head of Technical Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

公司管治

截至 2024年5月1日 止，CRISPR Therapeutics AG 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：4；董事會：9；股東權利：2；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。